Genomic characterisation of diffuse large B-cell lymphoma.

Area of Science:

• Oncology
• Genomics
• Hematology

Background:

• Diffuse large B-cell lymphoma (DLBCL) is a heterogeneous cancer with variable outcomes.
• Current classification (ABC/GCB) has limitations in predicting prognosis and guiding therapy.
• Improved subclassification and risk stratification are needed for better patient management.

Purpose of the Study:

• To review next-generation sequencing (NGS)-based analytical techniques for DLBCL molecular profiling.
• To discuss molecular classification models and their relevance to treatment selection.
• To explore the utility and practical considerations of genomic testing in DLBCL diagnostics.

Main Methods:

• Review of recent literature on NGS-based analytical techniques.
• Analysis of proposed molecular classification models for DLBCL.
• Discussion of emerging therapeutics and their molecular profiling requirements.

Main Results:

• Existing DLBCL classification methods may oversimplify biology and treatment selection.
• Comprehensive genomic profiling offers potential for improved prognostication.
• Standardization of molecular profiling techniques is yet to be achieved.

Conclusions:

• Genomic testing holds promise for DLBCL subclassification and risk stratification.
• Practical implementation in diagnostic labs requires consensus on optimal techniques.
• Molecular profiling may guide selection for emerging DLBCL therapies.